Trillium Therapeutics (Trillium Therapeutics) Treasury Stock : $0.00 Mil (As of Sep. 2021)

View and export this data going back to 2009. Start your Free Trial

What is Trillium Therapeutics Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Trillium Therapeutics's treasury stock for the quarter that ended in Sep. 2021 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Trillium Therapeutics Treasury Stock Historical Data

The historical data trend for Trillium Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trillium Therapeutics Treasury Stock Chart

Trillium Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Treasury Stock

Get a 7-Day Free Trial

Trillium Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Trillium Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Trillium Therapeutics (Trillium Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trillium Therapeutics Inc (NAS:TRIL) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 CambridgePark Drive, Suite 510, Cambridge, MA, USA, 02140

Website

https://www.trilliumtherapeutics.com

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.